Fesomersen sodium is under clinical development by Ionis Pharmaceuticals and currently in Phase II for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). According to GlobalData, Phase II drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fesomersen sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fesomersen sodium overview
Fesomersen sodium (IONIS-FXILRX) is under development for the treatment of clotting disorders, end-stage renal disease (ESRD) and thromboembolic events in patients with end-stage renal disease. The therapeutic candidate is a GalNAc conjugated 2'-MOE chimeric antisense oligonucleotide, which is administered through subcutaneous route. The drug candidate is acts by targeting coagulation factor XI. It is developed based on ligand-conjugated anti-sense (LICA) technology.
Ionis Pharmaceuticals overview
Ionis Pharmaceuticals (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in California, the US.
For a complete picture of Fesomersen sodium’s drug-specific PTSR and LoA scores, buy the report here.